From: A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
Nb
Observed
Median
Median cut-off to pass validation
Observed 25th percentile
Observed 75th percentile
Prediction error percents (PE%)
5382
0.72
± 15
-9.37
10.47
Absolute prediction error percents (|PE|%)
9.96
30
4.55
17.65